Centrosome aberrations in chronic myeloid leukemia correlate with stage of disease and chromosomal instability

Leukemia

Volumn 19, Issue 7, 2005, Pages 1192-1197

  Giehl, M ^a   Fabarius, A ^a   Frank, O ^a   Hochhaus, A ^a   Hafner, M ^b   Hehlmann, R ^a   Seifarth, Wolfgang ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b MANNHEIM UNIVERSITY OF APPLIED SCIENCES   (Germany)

Author keywords

Aneuploidy; Centrosome; Chromosomal instability; Chronic myeloid leukemia; Cytogenetic aberration

Indexed keywords

ADOLESCENT; ADULT; AGED; ANEUPLOIDY; ARTICLE; BLAST CELL CRISIS; CANCER GROWTH; CANCER STAGING; CENTROSOME; CHROMOSOMAL INSTABILITY; CHROMOSOME ABERRATION; CHROMOSOME TRANSLOCATION; CHRONIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOGENETICS; FEMALE; HUMAN; HUMAN CELL; KARYOTYPE; MALE; PRIORITY JOURNAL; PROGNOSIS;

EID: 21744458439     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2403779     Document Type: Article

References (40)

1. Sawyers CL. Chronic myeloid leukemia. N Engl J Med 1999; 340: 1330-1340.
2. Calabretta B, Perrotti D. The biology of CML blast crisis. Blood 2004; 103: 4010-4022.
3. Hehlmann R, Berger U, Hochhaus A. Chronic myeloid leukemia - a model for oncology. Ann Hematology 2005, (in press).
4. Hochhaus A, Weisser A, La Rosee P, Emig M, Müller MC, Saussele S et al. Detection and quantification of residual disease in chronic myelogenous leukemia. Leukemia 2000; 14: 998-1005.
5. Hehlmann R, Heimpel H. Current aspects of drug therapy in Philadelphia-positive CML: correlation of tumor burden with survival. Leuk Lymphoma 1996; 22 (Suppl 1): 161-167.
6. Müller MC, Gattermann N, Lahaye T, Deininger MW, Berndt A, Fruehauf S et al. Dynamics of BCR-ABL mRNA expression in first-line therapy of chronic myelogenous leukemia patients with imatinib or interferon alpha/ara-C. Leukemia 2003; 17: 2392-2400.
7. Futreal PA, Coin L, Marshall M, Down T, Hubbard T, Wooster R et al. A census of human cancer genes. Nat Rev Cancer 2004; 4: 177-183.
8. Johansson B, Fioretos T, Mitelman F. Cytogenetic and molecular genetic evolution of chronic myeloid leukemia. Acta Haematol 2002; 107: 76-94.
9. Mitelman F. Chromosomes, genes, and cancer. CA Cancer J Clin 1994; 44: 133-135.
10. Fabarius A, Hehlmann R, Duesberg PH. Instability of chromosome structure in cancer cells increases exponentially with degrees of aneuploidy. Cancer Genet Cytogenet 2003; 143: 59-72.
11. Duesberg P, Fabarius A, Hehlmann R. Aneuploidy, the primary cause of the multilateral genomic instability of neoplastic and preneoplastic cells. IUBMB Life 2004; 56: 65-81.
12. Marx J. Cell biology. Do centrosome abnormalities lead to cancer? Science 2001; 292: 426-429.
13. Hahn WC, Weinberg RA. Rules for making human tumor cells. N Engl J Med 2002; 347: 1593-1603.
14. Pihan G, Doxsey SJ. Mutations and aneuploidy: co-conspirators in cancer? Cancer Cell 2003; 4: 89-94.
15. Zhou H, Kuang J, Zhong L, Kuo WL, Gray JW, Sahin A et al. Tumour amplified kinase STK15/BTAK induces centrosome amplification, aneuploidy and transformation. Nat Genet 1998; 20: 189-193.
16. Pihan GA, Purohit A, Wallace J, Knecht H, Woda B, Quesenberry P et al. Centrosome defects and genetic instability in malignant tumors. Cancer Res 1998; 58: 3974-3985.
17. Pihan GA, Purohit A, Wallace J, Malhotra R, Liotta L, Doxsey SJ. Centrosome defects can account for cellular and genetic changes that characterize prostate cancer progression. Cancer Res 2001; 61: 2212-2219.
18. Carroll PE, Okuda M, Horn HF, Biddinger P, Stambrook PJ, Gleich LL et al. Centrosome hyperamplification in human cancer: chromosome instability induced by p53 mutation and/or Mdm2 overexpression. Oncogene 1999; 18: 1935-1944.
19. Schneeweiss A, Sinn HP, Ehemann V, Khbeis T, Neben K, Krause U et al. Centrosomal aberrations in primary invasive breast cancer are associated with nodal status and hormone receptor expression. Int J Cancer 2003; 107: 346-352.
20. Neben K, Giesecke C, Schweizer S, Ho AD, Krämer A. Centrosome aberrations in acute myeloid leukemia are correlated with cytogenetic risk profile. Blood 2003; 101: 289-291.
21. Krämer A, Schweizer S, Neben K, Giesecke C, Kalla J, Katzenberger T et al. Centrosome aberrations as a possible mechanism for chromosomal instability in non-Hodgkin's lymphoma. Leukemia 2003; 17: 2207-2213.
22. Bornens M. Centrosome composition and microtubule anchoring mechanisms. Curr Opin Cell Biol 2002; 14: 25-34.
23. Andersen JS, Wilkinson CJ, Mayor T, Mortensen P, Nigg EA, Mann M. Proteomic characterization of the human centrosome by protein correlation profiling. Nature 2003; 426: 570-574.
24. Krämer A, Ho AD. Centrosome aberrations and cancer. Onkologie 2001; 24: 538-544.
25. Tritarelli A, Oricchio E, Ciciarello M, Mangiacasale R, Palena A, Lavia P et al. p53 localization at centrosomes during mitosis and postmitotic checkpoint are ATM-dependent and require serine 15 phosphorylation. Mol Biol Cell 2004; 15: 3751-3757.
26. Krämer A, Lukas J, Bartek J. Checking out the centrosome. Cell Cycle 2004; 3: 1390-1393.
27. Nigg EA. Mitotic kinases as regulators of cell division and its checkpoints. Nat Rev Mol Cell Biol 2001; 2: 21-32.
28. Hochhaus A. Cytogenetic and molecular mechanisms of resistance to imatinib. Semin Hematol 2003; 40 (Suppl 2): 69-79.
29. Müller MC, Hordt T, Paschka P, Merx K, La Rosee P, Hehlmann R et al. Standardization of preanalytical factors for minimal residual disease analysis in chronic myelogenous leukemia. Acta Haematol 2004; 112: 30-33.
30. Hasford J, Pfirrmann M, Hehlmann R, Allan NC, Baccarani M, Kluin-Nelemans JC et al. A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa. Writing Committee for the Collaborative CML Prognostic Factors Project Group. J Natl Cancer Inst 1998; 90: 850-858.
31. Cross NC, Feng L, Bungey J, Goldman JM. Minimal residual disease after bone marrow transplant for chronic myeloid leukaemia detected by the polymerase chain reaction. Leuk Lymphoma 1993; 11 (Suppl 1): 39-43.
32. Denning-Kendall P, Singha S, Bradley B, Hows J. Cytokine expansion culture of cord blood CD34+ cells induces marked and sustained changes in adhesion receptor and CXCR4 expressions. Stem Cells 2003; 21: 61-70.
33. Fonatsch C, Schaadt M, Kirchner H, Diehl V. A possible correlation between the degree of karyotype aberrations and the rate of sister chromatid exchanges in lymphoma lines. Int J Cancer 1980; 26: 749-756.
34. ISCN##In: Mitelman F. (ed.) Guidelines for Cancer Cytogenetics, Supplement to: International System for Human Cytogenetic Nomenclature. Basel, S. Karger, 1995.
35. Zimmerman WC, Sillibourne J, Rosa J, Doxsey SJ. Mitosis-specific anchoring of gamma tubulin complexes by pericentrin controls spindle organization and mitotic entry. Mol Biol Cell 2004; 15: 3642-3657.
36. Lingle WL, Salisbury JL. Altered centrosome structure is associated with abnormal mitoses in human breast tumors. Am J Pathol 1999; 155: 1941-1951.
37. Kawamura K, Izumi H, Ma Z, Ikeda R, Moriyama M, Tanaka T et al. Induction of centrosome amplification and chromosome instability in human bladder cancer cells by p53 mutation and cyclin E overexpression. Cancer Res 2004; 64: 4800-4809.
38. Krämer A, Neben K, Ho AD. Centrosome replication, genomic instability and cancer. Leukemia 2002; 16: 767-775.
39. Nakajima T, Moriguchi M, Mitsumoto Y, Sekoguchi S, Nishikawa T, Takashima H et al. Centrosome aberration accompanied with p53 mutation can induce genetic instability in hepatocellular carcinoma. Mod Pathol 2004; 17: 722-727.
40. Borel F, Lohez OD, Lacroix FB, Margolis RL. Multiple centrosomes arise from tetraploidy checkpoint failure and mitotic centrosome clusters in p53 and RB pocket protein-compromised cells. Proc Natl Acad Sci USA 2002; 99: 9819-9824.